Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting on November 17, 2010 at 9:30 a.m. CST in Chicago, IL.
The poster, entitled "Discovery of a Novel Aptamer-Based Inhibitor of GPVI and its Matched Active Control Agent," illustrates the use of Regado's proprietary technology platform to identify a novel aptamer-control agent pair targeting GPVI. GPVI, which mediates collagen-induced platelet activation, is a novel target for a new antiplatelet agent. High levels of GPVI are associated with the onset of multiple diseases, including diabetes, ACS, peripheral vascular disease and stroke.
REG3, Regado's third development program, represents the first identification of an actively controllable GPVI antagonist and the first anti-platelet agent capable of providing active control of the duration and intensity of anti-platelet therapy. IND-enabling studies are ongoing and first-in-human clinical studies are anticipated to begin in 2011.
Routine lab tests fail to identify reliable biomarkers for long COVID, study finds